Table 4.

Clinical efficacy by EGFR and KRAS mutation status

EGFR mutationKRAS mutation
Positive (n = 7) n (%)Negative (n = 31) n (%)PPositive (n = 5) n (%)Negative (n = 33) n (%)P
Best objective response
    Partial response5 (71)6 (19)0.010 (0)11 (33)
    Stable disease5 (29)16 (52)3 (60)14 (42)
    Progressive disease0 (0)4 (13)0 (0)5 (15)
    Not assessable0 (0)5 (16)2 (40)3 (9)
Median TTP, mo6.95.00.303.85.60.39
    95% CI4.1-9.63.4-6.64.3-6.7
Median survival, moNot reached6.30.264.712.40.17
    95% CI0.5-12.20-9.84.7-20.2